235 related articles for article (PubMed ID: 22102202)
1. Laboratory diagnosis and management of von Willebrand disease in South Africa.
Meiring M; Coetzee M; Kelderman M; Badenhorst P
Semin Thromb Hemost; 2011 Jul; 37(5):576-80. PubMed ID: 22102202
[TBL] [Abstract][Full Text] [Related]
2. Laboratory diagnosis and management of von Willebrand disease in Turkey: Izmir experience.
Akin M; Kavakli K
Semin Thromb Hemost; 2011 Jul; 37(5):581-6. PubMed ID: 22102203
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of von Willebrand disease in Australia.
Favaloro EJ; Bonar R; Favaloro J; Koutts J
Semin Thromb Hemost; 2011 Jul; 37(5):542-54. PubMed ID: 22102198
[TBL] [Abstract][Full Text] [Related]
4. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
[TBL] [Abstract][Full Text] [Related]
5. Epidemiology, diagnosis, and management of von Willebrand disease in India.
Ghosh K; Shetty S
Semin Thromb Hemost; 2011 Jul; 37(5):595-601. PubMed ID: 22102205
[TBL] [Abstract][Full Text] [Related]
6. Guidelines for the evaluation of intravenous desmopressin and von Willebrand factor/factor VIII concentrate in the treatment and prophylaxis of bleedings in von Willebrand disease types 1, 2, and 3.
Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; van de Velden A; Berneman Z
Semin Thromb Hemost; 2006 Sep; 32(6):636-45. PubMed ID: 16977574
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis and management of adult patients with von Willebrand disease in South Australia.
Rodgers SE; Lloyd JV; Mangos HM; Duncan EM; McRae SJ
Semin Thromb Hemost; 2011 Jul; 37(5):535-41. PubMed ID: 22102197
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and management of von Willebrand disease: a developing country perspective.
Nair SC; Viswabandya A; Srivastava A
Semin Thromb Hemost; 2011 Jul; 37(5):587-94. PubMed ID: 22102204
[TBL] [Abstract][Full Text] [Related]
9. Laboratory diagnosis and molecular classification of von Willebrand disease.
Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
[TBL] [Abstract][Full Text] [Related]
10. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
[TBL] [Abstract][Full Text] [Related]
11. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
[TBL] [Abstract][Full Text] [Related]
12. Managing patients with von Willebrand disease type 1, 2 and 3 with desmopressin and von Willebrand factor-factor VIII concentrate in surgical settings.
Michiels JJ; van Vliet HH; Berneman Z; Schroyens W; Gadisseur A
Acta Haematol; 2009; 121(2-3):167-76. PubMed ID: 19506363
[TBL] [Abstract][Full Text] [Related]
13. Von Willebrand disease in children: diagnosis and management of a pediatric cohort in one single center in Argentina.
Bonduel M; Frontroth JP; Hepner M; Sciuccati G; Feliu-Torres A; Pieroni G
Semin Thromb Hemost; 2011 Jul; 37(5):560-7. PubMed ID: 22102200
[TBL] [Abstract][Full Text] [Related]
14. Laboratory diagnosis and molecular basis of mild von Willebrand disease type 1.
Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van Vliet HH
Acta Haematol; 2009; 121(2-3):85-97. PubMed ID: 19506353
[TBL] [Abstract][Full Text] [Related]
15. Comparative analysis and classification of von Willebrand factor/factor VIII concentrates: impact on treatment of patients with von Willebrand disease.
Budde U; Metzner HJ; Müller HG
Semin Thromb Hemost; 2006 Sep; 32(6):626-35. PubMed ID: 16977573
[TBL] [Abstract][Full Text] [Related]
16. PFA-100 monitoring of von Willebrand factor (VWF) responses to desmopressin (DDAVP) and factor VIII/VWF concentrate substitution in von Willebrand disease type 1 and 2.
van Vliet HH; Kappers-Klunne MC; Leebeek FW; Michiels JJ
Thromb Haemost; 2008 Sep; 100(3):462-8. PubMed ID: 18766263
[TBL] [Abstract][Full Text] [Related]
17. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
[TBL] [Abstract][Full Text] [Related]
18. Management of inherited von Willebrand disease in Italy: results from the retrospective study on 1234 patients.
Federici AB; Bucciarelli P; Castaman G; Baronciani L; Canciani MT; Mazzucconi MG; Morfini M; Rocino A; Schiavoni M; Oliovecchio E; Iorio A; Mannucci PM
Semin Thromb Hemost; 2011 Jul; 37(5):511-21. PubMed ID: 22102194
[TBL] [Abstract][Full Text] [Related]
19. Desmopressin therapy to assist the functional identification and characterisation of von Willebrand disease: differential utility from combining two (VWF:CB and VWF:RCo) von Willebrand factor activity assays?
Favaloro EJ; Thom J; Patterson D; Just S; Dixon T; Koutts J; Baccala M; Rowell J; Baker R
Thromb Res; 2009 Apr; 123(6):862-8. PubMed ID: 19064279
[TBL] [Abstract][Full Text] [Related]
20. Von Willebrand factor/factor VIII concentrates in the treatment of von Willebrand disease.
Batlle J; López-Fernández MF; Fraga EL; Trillo AR; Pérez-Rodríguez MA
Blood Coagul Fibrinolysis; 2009 Mar; 20(2):89-100. PubMed ID: 19786936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
